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Abstract
The reversal of the Rett syndrome disease process in the Mecp2 mouse model of Guy et al. (2007) has motivated
families and researchers to work on this condition. The reversibility in adult mice suggests that there is potentially
much to be gained from rational treatments applied to patients of any age. However, it may be difficult to strike
the right balance between enthusiasm on the one hand and realism on the other. One effect of this has been a
fragmentation of the “Rett syndrome community” with some groups giving priority to work aimed at a cure while
fewer resources are devoted to medical or therapy-based interventions to enhance the quality of life of affected
patients or provide support for their families.
Several possible therapeutic approaches are under development that, it is claimed and hoped, may lead to a “cure”
for patients with Rett syndrome. While all have a rationale, there are potential obstacles to each being both safe
and effective. Furthermore, any strategy that succeeded in restoring normal levels of MECP2 gene expression
throughout the brain carries potential pitfalls, so that it will be of crucial importance to introduce any clinical trials
of such therapies with great care.
Expectations of families for a radical, rational treatment should not be inflated beyond a cautious optimism. This is
particularly because affected patients with us now may not be able to reap the full benefits of a “cure”. Thus, interventions
aimed at enhancing the quality of life of affected patients should not be forgone and their importance should not be
minimised.
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Introduction
The road to a cure for Rett syndrome is paved with en-
couraging findings but also with many challenges.
Whilst optimism drives discovery, it is important for
those directly affected to be well informed. Scientists are
all well aware that gene therapy and gene editing are still
in their infancy. Setbacks during drug development are
almost a certainty. However, this is not such common
knowledge among the families of those affected. There is
not enough information available to lay persons to allow
realistic expectations to be set for the ‘cure’. No wonder
the public becomes despondent and distrustful of ex-
perts when those inevitable ‘bumps-on-the-road’ arise,
especially during clinical trials.
One consequence, perhaps, has been the polarisation
of the Rett syndrome community. Some believe all
efforts should be concentrated on finding a cure, instead
of seeking new ameliorative or palliative treatments.
Fewer now focus on care for the patients and families
who remain in need. Choosing to support a cure-
directed or a care-directed organisation may not be sim-
ply a matter of preference but is likely to relate to the
stage of the condition in the affected individual and their
pattern of adjustment to the diagnosis. The parents of
more recently diagnosed children, who may indeed be
better placed to benefit from new, cure-directed treat-
ments, will often have more energy for fund-raising and
more hope for a transformative treatment for their child.
Parents of older patients will often be more focused on
coping and caring, and will have adjusted to a different
pattern of family life. This has meant that care-directed
support groups have fewer resources for the continuing
needs of the families they support.
This fragmentation of the Rett community can be seen
as the result of complex social processes, including the
rise of social media and the internet, and the rise of ‘the
expert patient’. But, do we really want to place all our
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eggs in the single basket of transformative, cure-directed
treatments?
What we know about MECP2 and Rett syndrome
What we thought we knew about Rett syndrome before
the genetic cause was discovered was only partially cor-
rect. Yet, the things that we got wrong turned out to be
very interesting. For instance, MECP2 mutations are not
lethal in utero in males. They are simply more common
in females. This is because de novo mutation in the
MECP2 gene happens more frequently in the production
of sperm than of eggs, and therefore on the X chromo-
some donated by the father [1, 2]. In females, one of the
two X chromosomes comes from her father, whereas in
males the X always comes from the mother and the Y
chromosome from the father. Accordingly, the mutation
is found much more commonly in females. De novo mu-
tations in the paternal germline are more common than
previously thought. We now know that the risk of muta-
tions in sperm increases with exposure to environmental
toxins and with age [3].
It has also been learned that Rett syndrome appears to
be a neurodevelopmental disorder because of a “neces-
sary coincidence”. This is because the person who car-
ries the mutation is, of course, deficient in the MECP2
protein from the time they begin to grow and develop.
However, in a study that switched off production of the
protein in adult mice, the researchers showed the same
range of symptoms as those seen in mice which had the
mutation from conception and had therefore developed
with the disease [4]. It is likely that the same clinical pic-
ture would happen in adult humans if the gene were to
switch off later in life. This is good news because most
true neurodevelopmental disorders are not reversible in
adulthood. In contrast, the study by Guy J, Gan J, Self-
ridge J, Cobb S and Bird A [5] showed that it is possible
to reverse the symptoms of Rett syndrome in affected
adult mice. While those experiments did not provide a
clear route to develop human therapies, they did provide
an enormous motivator. These experiments indicated
that the potential benefits from any effective treatments
could be significant no matter the patient’s age. Further-
more, both studies also highlighted that any type of gene
therapy will need to deliver a working MECP2 gene
throughout the person’s life. It is not enough to deliver it
just during the child’s development.
There is some relation between the type of mutation
and the severity of certain symptoms in Rett syndrome.
However, this is inevitably obscured by variations of X
chromosome inactivation. Females have two X-
chromosomes, which means that they could have double
the amount of X-linked gene products compared to
males. But this does not happen, because one X-
chromosome is always (largely) inactive. In some
females, who are carriers of MECP2 mutations, the X
chromosome carrying the mutation can be preferentially
inactivated in some or most cells [6]. This often makes
their symptoms milder or even absent and they do not
develop Rett syndrome. This variability in X chromo-
some inactivation - frustratingly - makes it harder to dis-
tinguish the genetic from non-genetic modifiers of
disease severity. But it also provides an alternative route
for a cure (more on this below).
Challenges for gene therapy
One of the greatest known challenges to delivering a
permanent, “for ever”, cure for Rett syndrome comes
from what scientists call the ‘Goldilocks principle’. That
is, the amount of protein needs to be just right in each
brain cell, as too much MECP2 protein can be as bad as
too little. We know this because of another condition
called MECP2 duplication syndrome [7]. The males af-
fected by this condition have two copies of the MECP2
gene on their single X-chromosome, and so their cells
produce too much protein. The disease is also charac-
terised by mental disability and autistic-like behaviour.
Even worse, the levels of MECP2 do not need to be
much different for brain function to be disrupted.
Smaller deviations in protein function have been linked
with milder neurological and psychiatric symptoms. For
instance, female carriers of MECP2 duplication in which
85% or more cells inactivate the X chromosome carrying
the duplication (so that the duplication is functional in
< 15% of cells) exhibit anxiety and depression [8, 9].
Others with less favourable inactivation bias, have add-
itional intellectual disability and Rett-like symptoms [9,
10]. This potentially means that to really cure a person
with Rett syndrome we would need to deliver the right
levels of MECP2 to nearly all brain cells. Additionally, in
females, we would need to avoid delivering additional
copies of the gene to cells that already express the
healthy copy. This is a major challenge within the con-
straints of the currently available technologies. We may
have to accept that we can improve most of the severe
symptoms but not all. The person with Rett undergoing
gene therapy might still have underlying psychiatric
symptoms due to the sub-optimal levels of MECP2 in
parts of their brain.
Hopes of overcoming the ‘Goldilocks’ issue are based
on the process of X-chromosome inactivation. A treat-
ment that manages to inactivate the X chromosome car-
rying the damaged copy of the MECP2 gene could
resume production of functional MECP2 protein from
the intact copy on the other X chromosome. This is an
attractive treatment option as cells would use their own
regulatory functions to produce just the right amount of
MECP2 protein. We do not know how or why some
people are able to skew their X-chromosome
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inactivation, although the tendency to do this can run in
families and there might be damaging but unforeseen
consequences in some individuals. Of course, it will
sometimes happen simply by chance. Another approach
might be to activate the inactivated copy of the MECP2
gene in every cell. For this to work, however, reactivation
would need to be very selective to that single gene. We
do not yet have the technology to achieve this and,
again, there might be unintended consequences. Even if
we could do this, this approach would not offer a solu-
tion for all people with Rett syndrome. Those carrying
mutations that leave some residual MECP2 activity
would end up with too much protein function.
Gene editing is a powerful new technology that could
correct most of the MECP2 mutations causing Rett syn-
drome. It could overcome the ‘Goldilocks’ issue and would
work in both males and females. Gene editing uses molecu-
lar scissors to search a specific DNA sequence and remove
it. The faulty sequence is cut out and replaced with the cor-
rected DNA code. These molecular scissors are produced
in nature by bacteria. They use it to remove harmful viral
genes from their genome. This technology, called CRISPR/
Cas9, is already widely used to produce genetically altered
animals for research [11]. It recently made the news when
Ma H, Marti-Gutierrez N, Park SW, Wu J, Lee Y, Suzuki K,
Koski A, Ji D, Hayama T, Ahmed R, Darby H, Van Dyken
C, Li Y, Kang E, Park AR, Kim D, Kim ST, Gong J, Gu Y,
Xu X, Battaglia D, Krieg SA, Lee DM, Wu DH, Wolf DP,
Heitner SB, Belmonte JCI, Amato P, Kim JS, Kaul S and
Mitalipov S [12] successfully used it to correct a gene muta-
tion in human embryos. However, this technique will not
be approved for use in humans for some time, and the em-
bryos used in that research were destroyed. The method
worked relatively well for fertilised eggs before they had de-
veloped into embryos. Other studies have shown that this
approach is less effective once the fertilised eggs have devel-
oped into embryos [12]. This has a potential application to
preventing an inherited disorder being transmitted by an af-
fected parent but its application to the treatment of affected
patients appears much more difficult. This would be espe-
cially true for a condition such as Rett syndrome where the
key effects of the disease result from problems in the brain.
Previous studies in mice have shown that the technology is
sometimes not sufficiently precise and that it causes muta-
tions in unintended sites [13]. Even a very low level of in-
correct DNA targeting could cause disease in the individual
patient being treated, especially cancers. Mutations may
also be triggered that introduce recessive disease gene mu-
tations, unlikely to affect the treated patient but potentially
causing a range of different diseases in future generations.
Clearly, further refinement and safety testing will be re-
quired. Some suggest that a complete genome sequencing
of each patient would be required. This is to ensure that
the CRISPR/Cas9 would not target unwanted sites of the
patient’s genome. Related technological approaches that do
not modify DNA but RNA raise similar difficulties but
would in addition require life-long administration. These
approaches, therefore, may be less suitable as a therapeutic
strategy.
Finally, like other gene therapy strategies, there are
technical challenges with delivering the gene editing
constructs into the brain [14].
Perils of a late cure
Whichever strategy is chosen, there is no doubt that
some form of treatment for Rett syndrome will be avail-
able soon. Until now, 40 trials for Rett syndrome have
been registered in ClinicalTrials.gov. This is a registry of
publicly and privately supported clinical studies con-
ducted around the world. Most involve modulators of
neurotransmission, which aim to mitigate specific symp-
toms of the disease. These are symptomatic treatments,
not cures, as they don’t tackle the root cause, i.e. the dis-
ruption to the MECP2 gene that results in deficiency of
the MECP2 protein. Charities are moving away from
funding these types of studies. With costs of drug devel-
opment being so high, it would seem logical to invest
heavily in strategies for curing or reversing the disease,
instead of treatments that merely moderate symptoms
without ‘correcting’ the underlying problem. But could a
‘cure’ have unintended hazardous effects, be incomplete
or contraindicated for some?
Based on animal experiments, this appears to be a
warranted concern. The first set of adult mice to be
‘cured’ by Guy et al. [5] suffered high mortality. Nine out
of the first seventeen mice to be treated, all males, died
soon after treatment. The first treatment was given over
just 5 days. Survival was not problematic when the
reactivation of Mecp2 proceeded more slowly. The time-
scale of the mortality suggests that this may have been a
result of irregular breathing or erratic control of the
heart rhythm, although we do not know that for certain.
Certainly, it would be no surprise if autonomic instabil-
ity were to accompany any effective intervention in the
expression of the MECP2 gene (or the Mecp2 gene in
mice).
Furthermore, the re-expression of MECP2 in people
with Rett syndrome is likely to increase the volume of
their brains. We know that people with Rett syndrome
have smaller head circumference than neurotypical indi-
viduals. Thus, curing Rett might be problematic in
young people and adults whose skull sutures have fused.
There will be no room for the brain to grow. Cranial
surgery may be required to prevent brain damage or fa-
talities. It is the autonomic instability and raised intra-
cranial pressure that we might expect to be hazardous
over the days or weeks following an attempted ‘cure’ and
which would need to be monitored closely.
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We must also not underestimate the sensory and psy-
chological impacts of being ‘cured’. The experience of
regression early in the disease course causes very evident
distress. In individuals being ‘cured’, the process of re-
emerging from the cocoon imposed by the disease might
not be trouble-free. Some brain functions that will re-
awaken might be unpleasant, for instance pain. People
with Rett syndrome are reported to have reduced sensi-
tivity to pain [15]. Treated individuals may begin to ex-
perience greater than usual pain. Given the difficulties
with communication, it is expected that strategies of
pain assessment and management will need to be in
place for those receiving any attempt at a ‘cure’. Some of
these difficulties may be temporary but not all. Unfortu-
nately, for some young people and adults, the musculo-
skeletal deformities caused by Rett will be inexorably
irreversible. These individuals might end up requiring
life-long pain management therapies.
It is also worth considering the impact of an incom-
pletely effective rational therapy on behaviour. The ben-
efits are evident: any small improvement in cognition, in
control of breathing and speech, in ability to walk, in
ability to use hands would be welcomed by patients and
carers. However, affected individuals could become
physically fitter and abler while still having cognitive and
communication deficits, which may be associated with
psychological distress and confusion brought on by
treatment-mediated changes. Such individuals, may start
to display very challenging behaviours and become more
difficult to care for than before treatment. It is expected
that strategies would be put in place to help relatives
and carers manage challenging behaviours, whether tem-
porary or permanent, that may arise from an incomplete
cure.
Conclusions
By now you are probably asking yourself if you should
even hope for a cure. We would reply with a very defin-
ite, “Yes”, but also with some caution. Toddlers and
younger children with Rett have a very good chance of
experiencing a major improvement from new types of
treatment and even, perhaps, a cure. For those further
through childhood, the answer may be a middle ground
where we hope for the best but prepare for the worst. If
there is one lesson that the history of therapeutic discov-
eries has taught us, it is that throwing money at the
problem is no guarantee of the outcome you hoped for.
While that shouldn’t stop us from seeking a cure, per-
haps we should not give up the search for therapies that
bring benefit without necessarily achieving a cure. After
all, a child with Rett syndrome now will probably be a
young adult by the time “the cure” has first been devel-
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Glossary
Cas9
short for CRISPR associated protein 9. A genetic engineering tool used
to cut a specific DNA sequence. It is usually associated with a CRISPR
sequence.
CRISPR
abbreviation for Clustered Regularly Interspaced Short Palindromic
Repeats. A genetic engineering tool used to locate a specific DNA
sequence.
De novo mutations
a genetic alteration that is present for the first time in one family
member because of a mutation in a germ line cell of one of the
parents, or that arises in the fertilized egg itself during early
development.
DNA
Deoxyribonucleic acid, the molecule that stores the material of heredity




the complete set of genes or genetic material present in an organism
Germ line
cells that during reproduction pass on their genetic material to the
offspring. These include the gametes, sperm and egg, and the cells
from which they were produced.
MECP2 (italicised)
the gene that encodes methyl-CpG-binding protein 2 (MECP2). Muta-
tions in this gene cause Rett syndrome.
MECP2 (non-italicised)
a protein that controls the expression of other genes. This protein
appears to be essential for the normal function of brain cells.
MECP2 (all letters in capitals)
is the version of the gene or protein in humans, Mecp2 (only the first
letter in capitala) is the version in the mouse.
RNA
Ribonucleic acid, a material related to DNA. It has multiple roles in the
cell, especially in the synthesis of proteins. This includes acting as a
messenger molecule that conveys the information in DNA from the cell
nucleus into the cytoplasm so that it can be translated into protein.
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X chromosome
a sex chromosome, two of which are normally present in female cells
(designated XX) and only one in male cells (designated XY).
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